Lyell Immunopharma (LYEL) Operating Expenses (2020 - 2026)
Lyell Immunopharma (LYEL) posted Operating Expenses of $44.3 million for Q1 2026, down 65.32% sequentially from $127.6 million in Q4 2025, and down 22.85% YoY from $57.4 million in Q1 2025.
Lyell Immunopharma (LYEL) Operating Expenses (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Operating Expenses for 7 years, with the latest figure at $44.3 million in Q1 2026.
- Quarterly Operating Expenses fell 22.85% year-over-year to $44.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $256.3 million (down 28.92% YoY) and the FY2025 annual result came in at $269.4 million, down 24.91% from the prior year.
- Operating Expenses slipped to $44.3 million in Q1 2026 per LYEL's latest filing, from $127.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $201.2 million in Q4 2024 and troughed at $37.3 million in Q3 2025.
- A 5-year average of $70.1 million and a median of $59.5 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses soared 237.96% in 2024, then tumbled 36.54% in 2025.
- Over 5 years, Operating Expenses stood at $63.2 million in 2022, then decreased by 5.78% to $59.5 million in 2023, then jumped by 237.96% to $201.2 million in 2024, then sank by 36.54% to $127.6 million in 2025, then plunged by 65.32% to $44.3 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $44.3 million, $127.6 million, and $37.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | 47.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.34 Mn |
| Mar 31, 2026 | 44.26 Mn |
| Dec 31, 2025 | 127.65 Mn |
| Sep 30, 2025 | 37.27 Mn |
| Jun 30, 2025 | 47.15 Mn |
| Mar 31, 2025 | 57.37 Mn |
| Dec 31, 2024 | 201.16 Mn |
| Sep 30, 2024 | 50.54 Mn |
| Jun 30, 2024 | 51.54 Mn |
| Mar 31, 2024 | 55.58 Mn |
| Dec 31, 2023 | 59.52 Mn |
| Sep 30, 2023 | 59.06 Mn |
| Jun 30, 2023 | 65.93 Mn |
| Mar 31, 2023 | 62.62 Mn |
| Dec 31, 2022 | 63.17 Mn |
| Sep 30, 2022 | 66.44 Mn |
| Jun 30, 2022 | 73.00 Mn |
| Mar 31, 2022 | 69.13 Mn |
| Dec 31, 2021 | 50.36 Mn |
| Sep 30, 2021 | 51.92 Mn |